• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在一项针对绝经前淋巴结阴性乳腺癌的前瞻性研究中,S期分数和尿激酶型纤溶酶原激活剂比诺丁汉预后指数和组织学分级更能作为远处复发的标志物。

S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer.

作者信息

Malmström P, Bendahl P O, Boiesen P, Brünner N, Idvall I, Fernö M

机构信息

Jubileum Institute, Department of Oncology, Lund University Hospital, Lund, Sweden.

出版信息

J Clin Oncol. 2001 Apr 1;19(7):2010-9. doi: 10.1200/JCO.2001.19.7.2010.

DOI:10.1200/JCO.2001.19.7.2010
PMID:11283134
Abstract

PURPOSE

Histologic grade, Nottingham Prognostic Index (NPI), estrogen receptor (ER) and progesterone receptor (PgR) status, and tumor size have previously been shown to be important prognostic indicators for distant recurrence of breast cancer. The purpose of this study was to compare the prognostic value of these factors with flow cytometric S-phase fraction (SPF), urokinase plasminogen activator (uPA), and plasminogen activator inhibitor type 1 (PAI-1) in premenopausal patients with lymph node-negative breast cancer.

PATIENTS AND METHODS

In 237 consecutive premenopausal patients with lymph node-negative breast cancer and freshly frozen tumor material available, SPF, ER and PgR status, uPA and its inhibitor PAI-1, histologic grade, and NPI were evaluated.

RESULTS

SPF was univariately the most powerful prognostic factor for distant recurrence, followed by uPA, histologic grade, PgR, age, ER, NPI, and PAI-1, the latter being nonsignificant. Multivariate analysis revealed that neither NPI nor histologic grade was significant after adjustment for SPF, a fact that may be explained by the strong association between these factors. uPA was, however, an independent prognostic factor in addition to SPF, NPI, or histologic grade.

CONCLUSION

In this prospective study, SPF and uPA were found to be independent prognostic factors in premenopausal women with lymph node-negative breast cancer. We suggest that SPF, if performed under standardized conditions, can replace histologic grade as a selection instrument for adjuvant medical treatment. The value of the combination of SPF and uPA needs to be confirmed in an independent prospective trial.

摘要

目的

组织学分级、诺丁汉预后指数(NPI)、雌激素受体(ER)和孕激素受体(PgR)状态以及肿瘤大小先前已被证明是乳腺癌远处复发的重要预后指标。本研究的目的是比较这些因素与流式细胞术S期分数(SPF)、尿激酶型纤溶酶原激活剂(uPA)和1型纤溶酶原激活剂抑制剂(PAI-1)在绝经前淋巴结阴性乳腺癌患者中的预后价值。

患者与方法

对237例连续的绝经前淋巴结阴性乳腺癌患者且有新鲜冷冻肿瘤材料的患者,评估了SPF、ER和PgR状态、uPA及其抑制剂PAI-1、组织学分级和NPI。

结果

单因素分析显示,SPF是远处复发最有力的预后因素,其次是uPA、组织学分级、PgR、年龄、ER、NPI和PAI-1,后者无统计学意义。多因素分析显示,在调整SPF后,NPI和组织学分级均无统计学意义,这一事实可能由这些因素之间的强关联来解释。然而,除了SPF、NPI或组织学分级外,uPA是一个独立的预后因素。

结论

在这项前瞻性研究中,发现SPF和uPA是绝经前淋巴结阴性乳腺癌女性的独立预后因素。我们建议,如果在标准化条件下进行,SPF可以替代组织学分级作为辅助药物治疗的选择工具。SPF和uPA联合应用的价值需要在独立的前瞻性试验中得到证实。

相似文献

1
S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer.在一项针对绝经前淋巴结阴性乳腺癌的前瞻性研究中,S期分数和尿激酶型纤溶酶原激活剂比诺丁汉预后指数和组织学分级更能作为远处复发的标志物。
J Clin Oncol. 2001 Apr 1;19(7):2010-9. doi: 10.1200/JCO.2001.19.7.2010.
2
Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer.在一项针对淋巴结阴性的绝经前乳腺癌女性的前瞻性研究中,血管内皮生长因子是早期远处复发的有力预测指标。
Breast. 2008 Oct;17(5):484-91. doi: 10.1016/j.breast.2008.02.010. Epub 2008 May 27.
3
Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.尿激酶型纤溶酶原激活剂与其1型抑制剂的复合物预示576例淋巴结阴性乳腺癌患者预后不良。
Cancer. 2004 Aug 1;101(3):486-94. doi: 10.1002/cncr.20374.
4
DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase): association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients.
Int J Cancer. 2001 Jan 20;95(1):56-61. doi: 10.1002/1097-0215(20010120)95:1<56::aid-ijc1010>3.0.co;2-3.
5
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.8377例乳腺癌患者尿激酶型纤溶酶原激活剂及其抑制剂PAI-1预后影响的汇总分析。
J Natl Cancer Inst. 2002 Jan 16;94(2):116-28. doi: 10.1093/jnci/94.2.116.
6
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.纤溶酶原激活物抑制剂-1与原发性乳腺癌的预后
J Clin Oncol. 1994 Aug;12(8):1648-58. doi: 10.1200/JCO.1994.12.8.1648.
7
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.2780例乳腺癌患者纤溶酶原激活物的尿激酶系统与预后
Cancer Res. 2000 Feb 1;60(3):636-43.
8
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.侵袭标志物PAI-1无论是对原发性乳腺癌还是首次复发后的患者,在长期随访后仍是一个强有力的预后因素。
Breast Cancer Res Treat. 1999 Mar;54(2):147-57. doi: 10.1023/a:1006118828278.
9
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.乳腺癌细胞溶质提取物中高水平的尿激酶型纤溶酶原激活剂及其抑制剂PAI-1与预后不良相关。
Cancer Res. 1993 Jun 1;53(11):2513-21.
10
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.胞质肿瘤提取物中的1型纤溶酶原激活物抑制剂可预测低风险乳腺癌患者的预后。
Clin Cancer Res. 1997 Feb;3(2):233-9.

引用本文的文献

1
Acquired hyperfibrinolysis as the presenting sign of metastatic breast cancer: A case report.获得性高纤维蛋白溶解作为转移性乳腺癌的首发症状:一例报告。
Oncol Lett. 2023 Feb 2;25(3):106. doi: 10.3892/ol.2023.13692. eCollection 2023 Mar.
2
High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer.高CYP27A1表达是雌激素受体阳性原发性乳腺癌绝经前患者预后良好的生物标志物。
NPJ Breast Cancer. 2021 Sep 23;7(1):127. doi: 10.1038/s41523-021-00333-6.
3
Preoperative Routine Laboratory Markers for Predicting Postoperative Recurrence and Death in Patients with Breast Cancer.
预测乳腺癌患者术后复发和死亡的术前常规实验室指标
J Clin Med. 2021 Jun 13;10(12):2610. doi: 10.3390/jcm10122610.
4
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.激素受体阳性乳腺癌中基于依维莫司治疗反应的免疫系统及血管生成相关潜在替代生物标志物:一项探索性研究
Breast Cancer Res Treat. 2020 Nov;184(2):421-431. doi: 10.1007/s10549-020-05856-3. Epub 2020 Aug 7.
5
KLP-PI: a new prognostic index for luminal B HER-2-negative breast cancer.KLPPI:一种用于 luminal B HER-2 阴性乳腺癌的新预后指标。
Hum Cell. 2019 Apr;32(2):172-184. doi: 10.1007/s13577-018-00229-x. Epub 2018 Dec 17.
6
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis.管腔样HER2阴性IA期乳腺癌:一项采用倾向评分分析的长期结局多中心回顾性研究。
Oncotarget. 2017 Nov 24;8(68):112816-112824. doi: 10.18632/oncotarget.22643. eCollection 2017 Dec 22.
7
Prognostic value of routine laboratory variables in prediction of breast cancer recurrence.常规实验室变量对预测乳腺癌复发的预后价值。
Sci Rep. 2017 Aug 15;7(1):8135. doi: 10.1038/s41598-017-08240-2.
8
Modelling pulmonary microthrombosis coupled to metastasis: distinct effects of thrombogenesis on tumorigenesis.模拟与转移相关的肺微血栓形成:血栓形成对肿瘤发生的不同影响。
Biol Open. 2017 May 15;6(5):688-697. doi: 10.1242/bio.024653.
9
Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients.尿激酶型纤溶酶原激活物/纤溶酶原激活物抑制剂-1水平、人表皮生长因子受体2状态及传统组织学因素对淋巴结阴性乳腺癌患者生存的预后意义
Radiol Oncol. 2016 May 9;51(1):65-73. doi: 10.1515/raon-2016-0024. eCollection 2017 Mar 1.
10
Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer.乳腺钼靶密度和HER2过表达对浸润性乳腺癌患者诺丁汉预后指数的预后贡献。
BMC Cancer. 2016 Nov 2;16(1):833. doi: 10.1186/s12885-016-2892-y.